# Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases

> **NCT00019786** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 67 (estimated)

## Conditions studied

- Colorectal Cancer
- Islet Cell Tumor
- Liver Cancer
- Metastatic Cancer
- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** isolated perfusion
- **DRUG:** melphalan
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00019786
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2012-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019786, "Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00019786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*